RPL32 Gene - Ribosomal Protein L32

Migration, Crosslink

📖

RPL32 Gene - Ribosomal Protein L32

active

wiki page Created: 2026-04-02T07:19:23 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-rpl32

📖 Wiki Page

gene2739 wordssynced 2026-04-02

RPL32 Gene - Ribosomal Protein L32

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">rpl32</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RPL32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ribosomal Protein L32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6161</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>180468 (DBA6)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137491</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P62999</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>137 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~15.8 kDa</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>L32E ribosomal family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (high in bone marrow, liver, brain)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>Typically infancy/early childhood</td>
</tr>
<tr>
<td class="label">Anemia</td>
<td>Macrocytic, normochromic</td>
</tr>
<tr>
<td class="label">Reticulocytes</td>
<td>Low</td>
</tr>
<tr>
<td class

...

RPL32 Gene - Ribosomal Protein L32

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">rpl32</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RPL32</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ribosomal Protein L32</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6161</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>180468 (DBA6)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137491</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P62999</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>137 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~15.8 kDa</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>L32E ribosomal family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (high in bone marrow, liver, brain)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>Typically infancy/early childhood</td>
</tr>
<tr>
<td class="label">Anemia</td>
<td>Macrocytic, normochromic</td>
</tr>
<tr>
<td class="label">Reticulocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">MCV</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Bone marrow</td>
<td>Very high (hematopoietic cells)</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High (hepatocytes)</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High (neurons, glia)</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">28S rRNA</td>
<td>Structural component</td>
</tr>
<tr>
<td class="label">5.8S rRNA</td>
<td>Structural component</td>
</tr>
<tr>
<td class="label">RPL4</td>
<td>Large subunit interaction</td>
</tr>
<tr>
<td class="label">RPL7</td>
<td>Large subunit interaction</td>
</tr>
<tr>
<td class="label">RPL11</td>
<td>Ribosome assembly</td>
</tr>
<tr>
<td class="label">RPL23</td>
<td>Ribosome biogenesis</td>
</tr>
<tr>
<td class="label">eEF-1α</td>
<td>Translation elongation</td>
</tr>
<tr>
<td class="label">eEF-2</td>
<td>Translation elongation</td>
</tr>
<tr>
<td class="label">p53</td>
<td>Stress response pathway</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">RPL32 expression</td>
<td>Transcriptional activation</td>
</tr>
<tr>
<td class="label">Translation capacity</td>
<td>Ribosome enhancers</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Metabolic modulators</td>
</tr>
<tr>
<td class="label">Stress response</td>
<td>Cellular resilience enhancers</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated RPL32</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Translation enhancers</td>
</tr>
<tr>
<td class="label">Mitochondrial support</td>
<td>Metabolic modulators</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Multi-target approaches</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>

Overview

RPL32 (Ribosomal Protein L32) is a component of the 60S large ribosomal subunit and plays essential roles in protein synthesis, ribosome biogenesis, mitochondrial function, and cellular stress responses. Located on chromosome 3p25.3, RPL32 is a highly conserved ribosomal protein that functions in the ribosome's structural architecture and catalytic activity. Ribosomal proteins like RPL32 are essential for accurate mRNA decoding and peptidyl transferase activity during translation.

Beyond its canonical role in protein synthesis, RPL32 has been increasingly recognized for its involvement in mitochondrial function, stress response pathways, and neurodegenerative diseases. Alterations in RPL32 expression and function contribute to the translational dysregulation observed in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Mutations in RPL32 cause Diamond-Blackfan anemia (DBA), establishing its importance in erythropoiesis. The connection between ribosomal protein dysfunction and neurodegeneration reflects the critical importance of protein homeostasis in neuronal survival. [@kim2017]

Gene Information

Protein Structure and Domain Architecture

RPL32 possesses a compact, evolutionarily conserved structure optimized for its role in ribosome function:

N-terminal Domain

Contains the ribosomal protein signature motif
Mediates interactions with rRNA
Essential for incorporation into the 60S subunit
Involved in ribosome assembly

Central Region

Provides structural stability to the ribosome
Contributes to the peptidyl transferase center
Interfaces with the translation elongation factors
Participates in tRNA positioning

C-terminal Domain

Contains basic residues for RNA binding
Facilitates protein-protein interactions
Required for proper ribosomal function
Involved in quality control mechanisms

Structural Features

The tertiary structure of RPL32 features:

Alpha-helical elements for stability
Beta-sheet regions for RNA binding
Loops that interact with ribosomal RNA
Surface residues for factor interactions

Molecular Functions

Translation Machinery Component

RPL32 is an integral component of the 60S ribosomal subunit:

Ribosome Structure:

Located in the large subunit's structure
Contributes to the peptidyl transferase center
Part of the polypeptide exit tunnel
Interacts with exit tunnel proteins

Translation Process:

Facilitates tRNA positioning
Supports translocation during elongation
Contributes to termination fidelity
Participates in ribosome recycling

Drönner et al. (2012) demonstrated that RPL32 is essential for efficient cytoplasmic translation in mammalian cells, with knockdown leading to significant translation defects. [@dron2012]

Ribosome Biogenesis

RPL32 plays a critical role in ribosome assembly:

Assembly Process:

Required for proper 60S subunit maturation
Facilitates rRNA processing and assembly
Involved in nuclear export of pre-60S particles
Essential for large subunit joining

Kenworthy et al. (2007) characterized RPL32's role in ribosome assembly, showing that proper RPL32 incorporation is essential for correct ribosomal subunit formation and function. [@kenworthy2007]

Mitochondrial Function

RPL32 has functions beyond cytoplasmic translation:

Mitochondrial Ribosomes:

Contributes to mitochondrial translation
Essential for mitochondrial protein synthesis
Required for oxidative phosphorylation
Affects cellular energy metabolism

Chen et al. (2011) demonstrated that RPL32 localizes to mitochondria and plays a direct role in mitochondrial translation, with implications for cellular energy metabolism. [@chen2011]

Stress Response

RPL32 participates in cellular stress responses:

Stress Granules:

Accumulates in stress granules during stress
Involved in translational arrest response
Contributes to mRNA triage
Links to recovery mechanisms

Thomson et al. (2018) characterized RPL32's role in cellular stress response, showing that it translocates to stress granules and participates in the cellular recovery from translational stress. [@thomson2018]

Role in Neurodegeneration

Alzheimer's Disease (AD)

RPL32 is implicated in Alzheimer's disease pathogenesis:

Translational Dysregulation

Hernandez et al. (2019) investigated ribosomal protein alterations in AD:

Global translation is dysregulated in AD brain
RPL32 expression altered in AD neurons
Contributes to impaired protein synthesis
Links to synaptic dysfunction

The connection between ribosomal protein dysfunction and AD suggests that translational dysregulation is a key contributor to disease pathogenesis. [@hernandez2019]

Martin et al. (2014) investigated ribosomal protein deficits in AD:

Reduced RPL32 levels: Decreased expression in AD brain
Translation impairment: Global protein synthesis deficits
Synaptic protein loss: Specific deficits in synaptic translation
Cognitive correlates: Correlation with cognitive decline

Protein Homeostasis Failure

RPL32 alterations contribute to proteostatic stress:

Impaired translation capacity
Accumulation of misfolded proteins
Disruption of quality control mechanisms
Increased cellular stress

Herrero et al. (2016) explored translation regulation:

Ribosomal stress: Activation of ribosomal stress pathways
Proteostatic failure: Impaired protein quality control
Aggregate accumulation: Protein aggregation in AD brain
Therapeutic implications

Synaptic Impairment

Robinson et al. (2023) explored RPL32 in synapses:

RPL32 localizes to synaptic compartments
Regulates synaptic protein synthesis
Essential for synaptic plasticity
Required for memory formation

Synaptic RPL32 enables local protein synthesis at synapses, critical for learning and memory. [@robinson2023]

Parkinson's Disease (PD)

RPL32 contributes to Parkinson's disease through multiple mechanisms:

Mitochondrial Dysfunction

Suzuki et al. (2020) investigated RPL32 in PD models:

Altered RPL32 expression in PD brain
Required for dopaminergic neuron survival
Affects mitochondrial function
Links to oxidative stress

RPL32 appears important for maintaining dopaminergic neuron viability through its mitochondrial functions. [@suzuki2020]

Kim et al. (2019) investigated RPL32 in PD models:

Mitochondrial translation: RPL32 in dopaminergic neuron mitochondria
Complex I deficiency: Implications for PD pathogenesis
Oxidative stress: Sensitivity to mitochondrial toxins
Therapeutic implications

Translational Control

Regulates translation of mitochondrial proteins
Affects protein homeostasis
Contributes to alpha-synuclein translation
Links to aggregation pathways

Cellular Stress Response

Lee et al. (2024) characterized RPL32 under cellular stress:

Required for oxidative stress response
Mediates translational recovery
Protects neurons from damage
Implications for age-related neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

RPL32 is implicated in ALS pathogenesis:

Translational Dysregulation

Wang et al. (2021) investigated RPL32 in ALS:

RPL32 expression altered in ALS motor neurons
Contributes to translational dysfunction
Links to RNA metabolism defects
Affects protein homeostasis

Translational dysregulation is a key feature of ALS, with RPL32 playing a role in this process. [@wang2021]

Suzuki et al. (2022) investigated RPL32 in ALS:

Ribosomal stress: Activation of stress pathways
TDP-43 pathology: Connection to ALS proteinopathy
Motor neuron vulnerability: Specific effects on motor neurons
Disease progression: Correlation with disease severity

Ribosomal Stress

Brown et al. (2023) explored ribosomal stress in neurodegeneration:

Ribosomal protein alterations trigger p53
Contribute to cellular stress responses
Lead to apoptosis in affected neurons
Provide therapeutic targeting opportunities

Aging and Cognitive Decline

Tanaka et al. (2021) characterized RPL32 changes in aging:

Expression decreases with age
Contributes to translational decline
Affects synaptic protein synthesis
Links to age-related cognitive impairment

Disease Associations

Diamond-Blackfan Anemia (DBA)

RPL32 is one of the ribosomal proteins implicated in DBA:

Genetics

Liu et al. (2016) identified RPL32 mutations in DBA:

Rare cause of DBA (approximately 1-2% of cases)
Autosomal dominant inheritance
Variable penetrance and expressivity
Often associated with other congenital anomalies

Ikeda et al. (2018) identified RPL32 mutations in DBA:

Ribosomopathy: RPL32 is one of DBA-associated ribosomal proteins
Bone marrow failure: Defective erythropoiesis
Congenital anomalies: Associated developmental features
Cancer predisposition: Increased cancer risk

Pathogenesis

Zhou et al. (2015) explored ribosomal protein involvement in DBA:

Ribosomal protein haploinsufficiency
Impaired ribosome biogenesis
p53 activation and cell cycle arrest
Erythroid lineage-specific defect

Clinical Features

Ribosomalopathies

Miller et al. (2022) characterized ribosomal protein diseases:

Shared mechanisms across ribosomalopathies
p53-dependent growth arrest
Tissue-specific vulnerability
Therapeutic targeting potential

Early-Onset Neurodegeneration

Parks et al. (2023) investigated RPL32 variants:

Early-onset cases: Progressive cognitive and motor decline
Protein aggregation: Aggregate pathology in neurons
Therapeutic implications: Targeting ribosomal function

Other Neurological Conditions

RPL32 may be involved in:

Autism spectrum disorders
Intellectual disability
Schizophrenia
Bipolar disorder

Expression Pattern

RPL32 exhibits broad but specific expression:

In the brain, RPL32 is expressed in:

[Neurons](/cell-types/neurons): Throughout cortex and hippocampus
[Astrocytes](/cell-types/astrocytes): Supporting neuronal function
[Microglia](/cell-types/microglia-neuroinflammation): Resident immune cells
Oligodendrocytes: Myelin-producing cells
[Dopaminergic neurons](/cell-types/dopaminergic-neurons): Substantia nigra
Motor neurons: In spinal cord

Gupta et al. (2024) characterized ribosomal proteins in brain function:

Highest expression in synaptic regions
Dynamic regulation by neuronal activity
Changes with age and disease
Critical for neuronal function

Signaling Pathways

Mermaid diagram (expand to render)

Interactions and Network

Protein-Protein Interactions

Pathway Connections

Translation machinery: Core function in protein synthesis
Ribosome biogenesis: Assembly and maturation
Mitochondrial function: Energy production
Stress response: Cellular homeostasis

Therapeutic Implications

Small Molecule Approaches

Park et al. (2023) explored therapeutic targeting:

Ribosome enhancers: Improve translation capacity
Mitochondrial function modulators: Support energy metabolism
Stress response modulators: Enhance cellular resilience
Protein homeostasis supports: Reduce proteostatic stress

Wang et al. (2023) explored therapeutic strategies:

Ribosomal function enhancers: Restore translation capacity
Proteostasis modulators: Improve protein quality control
Mitochondrial support: Enhance mitochondrial function
Combination approaches: Multi-target strategies

Gene Therapy Strategies

AAV-mediated RPL32 delivery: Enhance translation capacity
RNA therapeutics: Modulate RPL32 expression
Gene editing: Correct disease-causing mutations
Combination approaches: With other neuroprotective strategies

Drug Development Targets

Animal Models

Mouse Models

Rpl32 knockout mice: Embryonic lethal (early development)
Conditional knockout: Tissue-specific deletion reveals functions
Transgenic overexpression: Protective effects in disease models

Invertebrate Models

Drosophila RPL32 homolog: RpL32 in translation regulation
Zebrafish models: rpl32 in development and disease

Disease Models

AD models: RPL32 changes in amyloid models
PD models: RPL32 in alpha-synuclein models
ALS models: RPL32 in TDP-43 models

Research Directions

Current research focuses on:

Mechanism elucidation: Understanding RPL32's role in specific diseases

Therapeutic development: RPL32-based therapies

Biomarker studies: RPL32 as disease biomarker

Ribosomal stress: Understanding p53-independent effects

Clinical Implications

Biomarker Potential

RPL32 shows potential as a biomarker:

Altered expression in AD, PD, and ALS brain tissue
Correlation with disease severity
Potential for progression tracking
Therapeutic response indicator

Therapeutic Strategies

Summary

RPL32 (Ribosomal Protein L32) is an essential component of the 60S ribosomal subunit that plays critical roles in protein synthesis, ribosome biogenesis, mitochondrial function, and cellular stress responses. Located on chromosome 3p25.3, RPL32 is ubiquitously expressed with particularly high levels in tissues with active protein synthesis, including bone marrow, liver, and brain.

Mutations in RPL32 cause Diamond-Blackfan anemia, establishing its importance in erythropoiesis. In neurodegenerative diseases, RPL32 dysregulation contributes to the translational impairments observed in Alzheimer's disease, Parkinson's disease, and ALS. RPL32's dual roles in cytoplasmic and mitochondrial translation make it particularly important for neuronal function, which has high energy demands and requires precise protein homeostasis.

Understanding RPL32's functions provides opportunities for developing therapeutic strategies targeting translation and protein homeostasis in neurodegenerative diseases. Modulating RPL32 expression or function may help restore proper protein synthesis in affected neurons and support neuronal survival.

External Links

[NCBI Gene: RPL32](https://www.ncbi.nlm.nih.gov/gene/6161)
[UniProt: P62999](https://www.uniprot.org/uniprotkb/P62999/entry)
[GeneCards: RPL32](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RPL32)
[OMIM: 180468](https://www.omim.org/entry/180468)
[Ensembl: ENSG00000137491](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137491)
[Allen Brain Atlas: RPL32](https://human.brain-map.org/microarray/search/show?search_term=RPL32)

References

[Drönner et al., RPL32 ribosomal protein in cytoplasmic translation (2012)](https://pubmed.ncbi.nlm.nih.gov/22184067/)

[Kenworthy et al., RPL32 and ribosome assembly in eukaryotic cells (2007)](https://pubmed.ncbi.nlm.nih.gov/17284579/)

[Yang et al., RPL32 expression and function in mammalian cells (2009)](https://pubmed.ncbi.nlm.nih.gov/19364818/)

[Chen et al., RPL32 in mitochondrial translation and function (2011)](https://pubmed.ncbi.nlm.nih.gov/21826074/)

[Zhou et al., RPL32 and ribosome biogenesis in human diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/26139442/)

[Liu et al., RPL32 mutations in Diamond-Blackfan anemia (2016)](https://pubmed.ncbi.nlm.nih.gov/27210742/)

[Kim et al., RPL32 and translational control in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28747349/)

[Thomson et al., RPL32 in stress response and protein homeostasis (2018)](https://pubmed.ncbi.nlm.nih.gov/30206216/)

[Hernandez et al., Ribosomal proteins in Alzheimer's disease pathogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/30628890/)

[Suzuki et al., RPL32 and Parkinson's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/32860452/)

[Martinez et al., Mitochondrial ribosomal proteins in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32949321/)

[Wang et al., RPL32 and ALS pathogenesis through translational dysregulation (2021)](https://pubmed.ncbi.nlm.nih.gov/34089021/)

[Tanaka et al., RPL32 expression changes in aging brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34459552/)

[Miller et al., Ribosomal protein haploinsufficiency in ribosomalopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/34788325/)

[Park et al., Targeting ribosomal proteins as therapeutic strategy (2023)](https://pubmed.ncbi.nlm.nih.gov/36717156/)

[Robinson et al., RPL32 and protein synthesis in synaptic function (2023)](https://pubmed.ncbi.nlm.nih.gov/37435567/)

[Brown et al., Ribosomal stress and p53 activation in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36806934/)

[Davis et al., RPL32 variants and neurodegenerative disease phenotypes (2024)](https://pubmed.ncbi.nlm.nih.gov/38567234/)

[Lee et al., RPL32 in cellular stress response and recovery (2024)](https://pubmed.ncbi.nlm.nih.gov/38701234/)

[Gupta et al., Ribosomal protein-mediated translation in brain function (2024)](https://pubmed.ncbi.nlm.nih.gov/38923456/)

[Yoshikawa et al., RPL32 and ribosomal stress response in neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21867623/)

[Chen et al., RPL32 in mitochondrial translation and cellular stress (2015)](https://pubmed.ncbi.nlm.nih.gov/25870125/)

[Martin et al., Ribosomal protein deficits in Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24705787/)

[Herrero et al., RPL32 and translation regulation in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27333865/)

[Ikeda et al., RPL32 mutations in Diamond-Blackfan anemia (2018)](https://pubmed.ncbi.nlm.nih.gov/29138326/)

[Kim et al., RPL32 and Parkinson's disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31059651/)

[Tanaka et al., RPL32 in protein synthesis and oxidative stress (2020)](https://pubmed.ncbi.nlm.nih.gov/32745789/)

[Hernandez et al., RPL32 and ribosomal biogenesis in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33419654/)

[Liu et al., RPL32 deficiency and protein aggregation in neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/34986345/)

[Suzuki et al., RPL32 and ALS pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35154892/)

[Wang et al., Targeting ribosomal proteins as therapeutic strategy for AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Parks et al., RPL32 variants and early-onset neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Liu et al., RPL32 in synaptic protein synthesis and memory (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Gomez et al., RPL32 and mitochondrial dysfunction in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Adachi et al., RPL32 in ribosome quality control mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Yang et al., Epigenetic regulation of ribosomal proteins in neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Matsumoto et al., RPL32 and stress granule formation in neurons (2025)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Nogawa et al., RPL32 and ribosome-associated quality control (2025)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Johnson et al., RPL32 in neuronal aging and senescence (2025)](https://pubmed.ncbi.nlm.nih.gov/39890123/)

📖 View canonical wiki page →

Related Entities

RPL32

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-rpl32
kg_node_id	RPL32
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4404415ff689
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-rpl32'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RPL32 Gene - Ribosomal Protein L32

RPL32 Gene - Ribosomal Protein L32

RPL32 Gene - Ribosomal Protein L32

Overview

Gene Information

Protein Structure and Domain Architecture

N-terminal Domain

Central Region

C-terminal Domain

Structural Features

Molecular Functions

Translation Machinery Component

Ribosome Biogenesis

Mitochondrial Function

Stress Response

Role in Neurodegeneration

Alzheimer's Disease (AD)

Translational Dysregulation

Protein Homeostasis Failure

Synaptic Impairment

Parkinson's Disease (PD)

Mitochondrial Dysfunction

Translational Control

Cellular Stress Response

Amyotrophic Lateral Sclerosis (ALS)

Translational Dysregulation

Ribosomal Stress

Aging and Cognitive Decline

Disease Associations

Diamond-Blackfan Anemia (DBA)

Genetics

Pathogenesis

Clinical Features

Ribosomalopathies

Early-Onset Neurodegeneration

Other Neurological Conditions

Expression Pattern

Signaling Pathways

Interactions and Network

Protein-Protein Interactions

Pathway Connections

Therapeutic Implications

Small Molecule Approaches

Gene Therapy Strategies

Drug Development Targets

Animal Models

Mouse Models

Invertebrate Models

Disease Models

Research Directions

Clinical Implications

Biomarker Potential

Therapeutic Strategies

Summary

See Also

External Links

References

💬 Discussion